Steven Fischkoff

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +15

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Edward Keystone, Arthur F. Kavanaugh, John T. Sharp et al. · Arthritis & Rheumatism · 2004 · 1.2K citations

Life Sciences, Immunology, Pharmacotherapy +17

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

L.B.A. van de Putte, Michel Malaise, J Sany et al. · Annals of the Rheumatic Diseases · 2004 · 620 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Daniel E. Furst, Michael Schiff, Roy Fleischmann et al. · PubMed · 2003 · 494 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*

Edward A. Panacek, John C. Marshall, Timothy E. Albertson et al. · Critical Care Medicine · 2004 · 384 citations

Veterinary Medicine, Immunology, Pharmacotherapy +16